RVNC Research and Charts

RVNC - Revance Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2025-02-06 (Delayed quote data 2025-02-05)

Last 3.65	Change ⇑ +0.01 (+0.27%)	Volume 4,119,317
	Open 3.65	High 3.66	Low 3.65

8EMA (Daily) 3.63	40EMA (Daily) 3.59	50EMA (Daily) 3.67	STO (Daily) 86.112	MACD Hist (Daily) 0.042
8EMA (Weekly) 3.594	40EMA (Weekly) 4.83	50EMA (Weekly) 5.52	STO (Weekly) 18.415	MACD Hist (Weekly) 0.118


Company Profile
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are Product and the Service Segment. The Products segment generates maximum revenue which is engaged in research and development of aesthetic and therapeutic products.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.